Chen, Zhiyuan
Zheng, Wen
Wu, Qianhui
Chen, Xinghui
Peng, Cheng
Tian, Yuyang
Sun, Ruijia
Dong, Jiayi
Wang, Minghan
Zhou, Xiaoyu
Zhao, Zeyao
Zhong, Guangjie
Yan, Xuemei
Liu, Nuolan
Hao, Feiran
Zhao, Sihong
Zhuang, Tingyu
Yang, Juan
Azman, Andrew S.
Yu, Hongjie
Funding for this research was provided by:
Key Program of the National Natural Science Foundation of China (82130093)
US National Institutes of Health (R01 AI135115)
Article History
Received: 12 November 2021
Accepted: 14 March 2022
First Online: 4 April 2022
Declarations
:
: Not applicable.
: Not applicable.
: H.Y. has received research funding from Sanofi Pasteur, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd. Except for research funding from SINOVAC Biotech Ltd, which is related to the data analysis of clinical trials of immunogenicity and safety of CoronaVac, the others are not related to COVID-19. All other authors report no competing interests.